Prostate Cancer: Diagnosis and evaluation: Difference between revisions
Urology4all (talk | contribs) No edit summary |
Urology4all (talk | contribs) |
||
| (97 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
[[Category:Prostate Cancer]] | [[Category:Prostate Cancer]] | ||
'''See [[AUA: Early Detection of Prostate Cancer (2023)|2023 AUA Guidelines on Early Detection of Prostate Cancer]]''' | |||
'''Includes [https://pubmed.ncbi.nlm.nih.gov/33661093/ 2021 CUA Best Practice Report on PET/CT and PET/MR in Prostate Cancer]''' | '''Includes [https://pubmed.ncbi.nlm.nih.gov/33661093/ 2021 CUA Best Practice Report on PET/CT and PET/MR in Prostate Cancer]''' | ||
| Line 15: | Line 17: | ||
== Diagnosis and Evaluation == | == Diagnosis and Evaluation == | ||
=== UrologySchool.com Summary === | |||
* '''History and Physical Exam''' | |||
* '''Labs''' | |||
** '''PSA''' | |||
* '''Imaging''' | |||
** '''MRI''' | |||
*'''Other''' | |||
**'''Prostate biopsy''' | |||
***'''If suspicion for clinically significant prostate cancer (based on history, physical exam, PSA, and MRI) and diagnosis will influence management.''' | |||
=== <span style="color:#ff0000">History and physical exam</span> === | === <span style="color:#ff0000">History and physical exam</span> === | ||
| Line 29: | Line 42: | ||
*#*** '''Is a TRUS biopsy of benefit in a 95 year-old male with a PSA 400 ng/mL ?''' | *#*** '''Is a TRUS biopsy of benefit in a 95 year-old male with a PSA 400 ng/mL ?''' | ||
*#** '''Is the patient a candidate for treatment ([[AUA: Clinically Localized Prostate Cancer (2017)|contraindications to radiotherapy]], for example)?''' | *#** '''Is the patient a candidate for treatment ([[AUA: Clinically Localized Prostate Cancer (2017)|contraindications to radiotherapy]], for example)?''' | ||
*#** '''<span style="color:#ff0000">Family history of</span> [ | *#** '''<span style="color:#ff0000">Family history</span>''' | ||
*#***'''<span style="color:#ff0000">Criteria for "strong" family history (2):</span>''' | |||
*#***# '''<span style="color:#ff0000">≥1 brother or father OR ≥2 male relatives with one of the following (3):</span>''' | |||
*#***##'''<span style="color:#ff0000">Diagnosed with prostate cancer at age <60 years</span>''' | |||
*#***##'''<span style="color:#ff0000">Any of whom died of prostate cancer</span>''' | |||
*#***##'''<span style="color:#ff0000">Any of whom had metastatic prostate cancer.</span>''' | |||
*#***# '''<span style="color:#ff0000">Family history of other cancers with ≥2 cancers in hereditary breast and ovarian cancer syndrome or Lynch syndrome spectrum.</span>''' | |||
*#***#* '''<span style="color:#ff0000">Hereditary breast and ovarian cancer syndrome</span>''' | |||
*#***#**'''<span style="color:#ff0000">Associated cancers (5):[https://www.ncbi.nlm.nih.gov/books/NBK1247/]</span>''' | |||
*#***#*#'''<span style="color:#ff0000">Breast (male and female)</span>''' | |||
*#***#*#'''<span style="color:#ff0000">Ovarian</span>''' | |||
*#***#*#'''<span style="color:#ff0000">Prostate</span>''' | |||
*#***#*#'''<span style="color:#ff0000">Pancreatic</span>''' | |||
*#***#*#'''<span style="color:#ff0000">Melanoma</span>''' | |||
*#***#*'''<span style="color:#ff0000">Lynch syndrome</span>''' | |||
*#***#**'''<span style="color:#ff0000">Associated cancers (11)</span>[https://www.ncbi.nlm.nih.gov/books/NBK431096/]''' | |||
*#***#**#'''<span style="color:#ff0000">Colorectal (20-80%) (most common)</span>''' | |||
*#***#**#'''<span style="color:#ff0000">Gynecologic</span>''' | |||
*#***#**## '''<span style="color:#ff0000">Endometrial (15-60%) in females (second most common)</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Ovarian cancer (1-38%) in females</span>''' | |||
*#***#**#'''<span style="color:#ff0000">Urologic</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Urothelial (1-18%), includes upper urinary tract and bladder</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Prostate</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Adrenal[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739861/ §]</span>''' | |||
*#***#**#'''<span style="color:#ff0000">Other gastrointestinal</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Gastric cancers (1-13%)</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Hepatobiliary</span>''' | |||
*#***#**##'''<span style="color:#ff0000">Small bowel</span>''' | |||
*#***#**#'''<span style="color:#ff0000">Skin</span>''' | |||
*#***#**#*'''<span style="color:#ff0000">Sebaceous adenoma, sebaceous epithelioma, sebaceous adenocarcinoma, keratoacanthoma, and squamous cell carcinoma[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423888/]</span>''' | |||
*#***#**# '''<span style="color:#ff0000">Brain</span>''' | |||
*#***#**#'''<span style="color:#ff0000">Inconsistent: Pancreas, breast, (prostate)</span>''' | |||
*#**'''<span style="color:#ff0000">Patients with a "strong" family history should ideally be genotyped</span>[https://pubmed.ncbi.nlm.nih.gov/37096582/]''' | |||
*#***'''Genotype is to ascertain whether there is presence of a pathogenic variant (e.g., BRCA1/2, Lynch Syndrome, ATM, CHEK2) or one or more of a growing set of identified germline DNA damage-repair mutations found in patients with metastatic prostate cancer diagnoses.''' | |||
*# '''Patient preference for investigations/treatment''' | *# '''Patient preference for investigations/treatment''' | ||
*#* '''Benefits/harms of treatment (sexual function, for example)''' | *#* '''Benefits/harms of treatment (sexual function, for example)''' | ||
| Line 37: | Line 83: | ||
** '''<span style="color:#ff0000">Digital rectal examination</span>''' | ** '''<span style="color:#ff0000">Digital rectal examination</span>''' | ||
*** '''A palpable tumour and the extent is associated with local disease extent (clinical T stage)''' | *** '''A palpable tumour and the extent is associated with local disease extent (clinical T stage)''' | ||
*** '''In a screened population, an abnormal DRE is | ****'''Can both overestimate and underestimate the extent of disease because of its poor sensitivity and lack of reproducibility''' | ||
*** ''' | ***** '''Consider useful to detect presence, but not useful to assess stage''' | ||
*** ''' | *** '''In a screened population, an abnormal DRE is associated with an increased risk for detecting high-grade (Gleason 8 to 10) prostate cancer''' | ||
*** '''When DRE and PSA tests are used in prostate cancer screening, detection rates are higher with PSA testing alone vs. DRE alone, and highest with the tests together | ***'''<span style="color:#ff0000">Indications (2023 AUA Guidelines on Early Detection of Prostate Cancer[https://pubmed.ncbi.nlm.nih.gov/23659877/])</span>''' | ||
****'''<span style="color:#ff0000">Screening</span>''' | |||
**** | *****'''<span style="color:#ff0000">Should not use DRE as the sole screening method.</span>''' | ||
******'''The primary screening modality recommended for the early detection of prostate cancer is a PSA blood test.''' | |||
*****'''<span style="color:#ff0000">Insufficient evidence to support adding DRE to PSA-based prostate cancer screening.</span>''' | |||
******For various reasons, clinicians may choose to complement PSA screening with DRE based on SDM. | |||
*******When DRE and PSA tests are used in prostate cancer screening, detection rates are higher with PSA testing alone vs. DRE alone, and highest with the tests together[https://pubmed.ncbi.nlm.nih.gov/28012755/] | |||
*****[[AUA: Prostate Cancer Screening (2018)|2018 AUA]] and [[CUA: Prostate Cancer Screening (2017)|2017 CUA]] Guidelines support the role of DRE in screening | |||
****'''<span style="color:#ff0000">Elevated PSA[https://pubmed.ncbi.nlm.nih.gov/23659877/]</span>''' | |||
*****'''<span style="color:#ff0000">If PSA ≥ 2 ng/mL, strongly consider supplementary DRE to establish risk of clinically significant prostate cancer.</span>''' | |||
******Highest utility of DRE in randomized trials is demonstrated in the workup of patients with an elevated PSA.*******In contrast to a screening application, use of DRE subsequent to the screening encounter may be of value. | |||
********In patients undergoing prostate biopsy for an elevated PSA during screening, abnormal DRE improves the PPV for any prostate cancer and GG2+ detection | |||
=== <span style="color:#ff0000">Labs</span> === | === <span style="color:#ff0000">Labs</span> === | ||
* ''' | |||
==== PSA[https://pubmed.ncbi.nlm.nih.gov/12525533/] ==== | |||
** ''' | * '''<span style="color:#ff0000">Serum PSA is the single test with the highest positive predictive value for prostate cancer</span>''' | ||
**'''Although as many as 20-30% of males evaluated for an elevated PSA level may be diagnosed with prostate cancer after TRUS biopsy, as many as 70-80% will not be found to have cancer''' | |||
*'''<span style="color:#ff0000">If newly elevated PSA (no prior PSA or current value inconsistent with previous trend), then repeat the PSA prior to a secondary biomarker, imaging, or biopsy.</span>''' | |||
** ''' | **'''In people with a newly elevated PSA, it will return to a normal level in 25-40% upon retesting.''' | ||
**'''<span style="color:#ff0000">Half-life: 2-3 days</span>[https://pubmed.ncbi.nlm.nih.gov/9555548/][https://pubmed.ncbi.nlm.nih.gov/8973698/]''' | |||
**'''A repeat PSA in a few months is recommended, though it can be shortened or lengthened depending on other clinical factors.''' | |||
===== Causes of elevated PSA ===== | |||
# '''<span style="color:#ff0000">Prostate disease</span> (BPH, prostatitis, prostate cancer, etc.)''' | |||
# '''<span style="color:#ff0000">Prostate manipulation</span> (prostate massage, biopsy, etc.)''' | |||
*** ''' | * '''<span style="color:#ff0000">Prostate Disease</span>''' | ||
** '''<span style="color:#ff0000"> | **'''<span style="color:#ff0000">Prostate cancer</span>''' | ||
** | ***'''<span style="color:#ff0000">Prostate cancer cells produce less PSA than normal prostatic tissue</span>''' | ||
** | ***'''<span style="color:#ff0000">PSA becomes elevated in prostate cancer due to disruption of cellular architecture within the prostate gland</span>''' | ||
*** ''' | **** '''<span style="color:#ff0000">Prostate cancer lacks basal cells</span>, resulting in the disruption of the basement membrane and normal lumen architecture''' | ||
****''' | *** '''<span style="color:#ff0000">PSA levels are inversely correlated with risks of</span>''' | ||
*****''' | ****'''<span style="color:#ff0000">Pathologically organ-confined (pT2) disease</span>''' | ||
*****''' | ***** '''<span style="color:#ff0000">PSA < 4.0 ng/mL: 80%</span>''' | ||
****''' | ***** '''<span style="color:#ff0000">PSA 4-10 ng/mL: 66%</span>''' | ||
*****''' | ***** '''<span style="color:#ff0000">PSA > 10.0 ng/mL: <50%</span>''' | ||
**** '''<span style="color:#ff0000">Pelvic lymph node involvement</span>''' | |||
***** '''PSA >20 ng/ml: 20%''' | |||
** | ***** '''PSA >50 ng/mL: 75%''' | ||
** | *'''<span style="color:#ff0000">Prostate manipulation</span>''' | ||
** | **'''<span style="color:#ff0000">May influence PSA in a clinically meaningful way[https://pubmed.ncbi.nlm.nih.gov/23659877/]</span>''' | ||
** | **#'''<span style="color:#ff0000">Urinary tract infections</span>''' | ||
**#'''<span style="color:#ff0000">Instrumentation (e.g., prostate biopsy, cystoscopy, urinary retention, recent bladder catheterization)</span>''' | |||
**##'''<span style="color:#ff0000">Biopsy</span>[https://pubmed.ncbi.nlm.nih.gov/7691013/][https://pubmed.ncbi.nlm.nih.gov/10376076/]''' | |||
** | **##*'''Results in immediate elevation in the serum PSA level, with a median increase of 6-8 ng/mL''' | ||
** | **##*'''Usually returns to a stable, baseline level within 2-3 weeks''' | ||
** | **##'''<span style="color:#ff0000">Cystoscopy</span>[https://pubmed.ncbi.nlm.nih.gov/7691013/][https://pubmed.ncbi.nlm.nih.gov/10376076/]''' | ||
**##*Studies have found that cystoscopy results in small (0.05-0.15 ng/mL) increase in PSA and have suggested that serum PSA determination after either a flexible or a rigid cystoscopy is accurate and reliable | |||
*** | **##'''<span style="color:#ff0000">TURP</span>[https://pubmed.ncbi.nlm.nih.gov/7691013/][https://pubmed.ncbi.nlm.nih.gov/10376076/]''' | ||
**##*'''Results in immediate elevation in the serum PSA level, with a median increase of 6-13 ng/mL[https://pubmed.ncbi.nlm.nih.gov/7691013/]''' | |||
** | **##*'''Usually returns to a stable, baseline level within 2-3 weeks[https://pubmed.ncbi.nlm.nih.gov/7691013/]''' | ||
** | **##'''<span style="color:#ff0000">Recent bladder catheterization</span>''' | ||
*** | **##*One study found very little effect on PSA level at day 1 and 3 after catheterization and suggested that routine evaluation PSA in patients with recent catheterization.[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5393098/] | ||
***# '''<span style="color:#ff0000"> | **'''<span style="color:#ff0000">Unlikely to influence PSA in a clinically meaningful way[https://pubmed.ncbi.nlm.nih.gov/23659877/]''' | ||
**#'''<span style="color:#ff0000">DRE</span>''' | |||
**#*'''Can lead to slight increases in serum PSA level; however, the resultant change in PSA values falls within the error of the assay and''' '''<span style="color:#ff0000">rarely causes false-positive test results</span>''' | |||
**#'''<span style="color:#ff0000">Bicycle riding</span>''' | |||
**#*With long-distance (> 55km) bicycle rides, PSA levels increasing by ≈10% | |||
**#'''<span style="color:#ff0000">Ejaculation</span>''' | |||
** | **#*'''Studies examining the effect of ejaculation on serum PSA have reported conflicting results.''' | ||
** | **#**Most controlled studies evaluating ejaculation suggest it either does not significantly impact or modestly increases (~10%) PSA. | ||
**#*'''<span style="color:#ff0000">A repeat PSA test after 48 hours of sexual abstinence may be helpful for interpreting serum PSA levels that are minimally elevated or newly elevated.</span>''' | |||
* | **#'''<span style="color:#ff0000">TRUS</span>[https://pubmed.ncbi.nlm.nih.gov/10376076/]''' | ||
**#*'''Results in small (0.3 ng/mL) increase in PSA''' | |||
**#*'''Serum PSA determination after TRUS without biopsy is accurate and reliable''' | |||
**'''Most of the rise in total PSA after prostate manipulation is contributed by the free (non-bound) component.''' | |||
*** '''In general, complexed PSA is the most stable component and relatively little rise occurs following prostate manipulation.''' | |||
===== Clinical factors that influence PSA ===== | |||
* '''<span style="color:#ff0000">In the absence of prostate cancer, PSA levels vary with (4):</span>''' | |||
*# '''<span style="color:#ff0000">Age</span>''' | |||
*# '''<span style="color:#ff0000">Race</span>''' | |||
*#* '''African-American males without prostate cancer have higher PSA values than Caucasians''' | |||
*# '''<span style="color:#ff0000">Prostate volume</span>''' | |||
*#* '''PSA increases 4%/mL prostate volume''' | |||
*#** '''BPH surgery can lead to reductions in the serum PSA level''' | |||
*#** '''Annual rate of change in PSA is higher in men with BPH compared to men without BPH''' | |||
*# '''<span style="color:#ff0000">BMI</span>''' | |||
*#* '''<span style="color:#ff0000">Increasing BMI independently associated with decreasing serum PSA</span>''' | |||
===== PSA-derivatives ===== | |||
*'''Concept is to adjust for known factors that can influence PSA (age, volume, race (BMI can also influence PSA)) and improve specificity''' | |||
**'''Patients with prostate cancer may have a “normal” PSA (i.e. false-negative) and patients without prostate cancer may have "elevated" PSA (i.e. false-positive); PSA is neither sensitive nor specific, particularly between 4.0-10.0 ng/dL.''' | |||
======<span style="color:#ff0000">Volume-adjusted PSA</span>====== | |||
*'''Concept is to reduce confounding from BPH''' | |||
*'''Includes PSA divided by prostate volume (PSA density, PSAD), complexed PSAD (cPSA divided by prostate volume), and PSA transition zone density (PSA divided by transition zone volume, PSAT)''' | |||
**'''<span style="color:#ff0000">A PSAD of ≥0.15 has been proposed for recommending prostate biopsy in men with PSA levels between 4-10 ng/mL and normal DRE</span>''' | |||
**'''PSAT has been developed to adjust for the transition zone volume, the major determinant of serum PSA in men without prostate cancer''' | |||
*'''Prostate volume typically determined by US''' | |||
====== <span style="color:#ff0000">Age-/race- adjusted PSA</span>====== | |||
*'''Race: African-American men without prostate cancer have higher PSA values than Caucasian men''' | |||
*'''Age: PSA normally increases with age''' | |||
**'''The mature prostate is between 20-25 g and remains relatively constant until ≈age 50, when the gland enlarges in many men; the average prostate volume in a 60-70 year old is ≈48 g''' | |||
======<span style="color:#ff0000">PSA velocity</span>====== | |||
*'''Short-term fluctuations in PSA can occur between measurements in the presence or absence of prostate cancer, primarily as a result of physiologic variation. However, the rate of change in PSA (PSAV)—PSA corrected for the elapsed time between measurements is associated with the risk for prostate cancer''' | |||
*'''<span style="color:#ff0000">PSAV > 0.75 ng/mL/year has been shown to be a specific marker for the presence of prostate cancer in men with PSA levels between 4-10 ng/mL</span>''' | |||
*'''There are conflicting studies on whether PSAV provides more information than total PSA in predicting disease aggressiveness''' | |||
======<span style="color:#ff0000">Free-PSA (fPSA)</span>====== | |||
* '''<span style="color:#ff0000">%fPSA varies directly with age and volume, and indirectly with total PSA. Does not vary by race.</span>''' | |||
*'''<span style="color:#ff0000">Low %fPSA is associated with increased risk of prostate cancer''' | |||
**'''PSA produced by malignant cells escapes proteolytic processing more frequently, resulting in a <span style="color:#ff0000">greater fraction of serum PSA complexed</span> to α1-antichymotrypson and a lower %fPSA compared to men without cancer''' | |||
**'''<span style="color:#ff00ff">Catalona et al. (1998)</span>''' | |||
***Population: | |||
****Prospective cohort study of 773 men aged 50-75 enrolled primarily through screening centers with PSA 4-10 and palpably benign gland that underwent diagnostic biopsy | |||
*****49% had cancer, 51% had benign disease | |||
*** Primary outcome: | |||
****%fPSA that maintained 95% sensitivity for PC detection | |||
***Results: | |||
****%fPSA was inversely associated with risk of cancer | |||
****AUC 0.72 %fPSA vs. 0.53 total PSA | |||
****%fPSA cut-off: | |||
*****≤25: sensitivity: 95%, specificity 20% | |||
***** ≤22: sensitivity 90%, specificity 29% | |||
****INSERT FIGURE | |||
***Catalona, William J., et al. "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial." ''Jama'' 279.19 (1998): 1542-1547. | |||
**'''%fPSA as a test is FDA-approved in men with a total PSA 4-10ng/mL and negative DRE''' | |||
***'''%fPSA is most useful in the setting of PSA levels < 10ng/ml because the PPV of tPSA > 10- 20ng/ml has been shown to be ≈80%; it’s utility in PSA <4.0ng/ml is unknown''' | |||
*** '''No %fPSA threshold has been established, proposed cut points generally range from 15-25%''' | |||
***'''Debate remains surrounding the utility of %fPSA as a prognostic biomarker''' | |||
*'''Complexed-PSA (as opposed to the free-PSA)''' | |||
**'''Overall, at a high sensitivity, cPSA provides higher specificity than tPSA and comparable specificity to %fPSA in prostate cancer detection. A potential advantage of cPSA is the requirement for one assay''' | |||
*'''<span style="color:#ff0000">5ARIs lower total PSA levels by ≈50% after 12 months of treatment</span>''' | |||
** '''With the use of 5ARIs, fPSA decreases in a similar fashion to tPSA, and the %fPSA is not altered significantly''' | |||
**'''Finasteride 1 mg (Propecia) used for male pattern hair loss (androgenic alopecia) results in the same decline in serum PSA levels as the 5-mg dosage used for the treatment of BPH''' | |||
**'''In the PCPT trial, PSA had statistically significantly better sensitivity and AUC for detecting prostate cancer in the finasteride arm[https://www.ncbi.nlm.nih.gov/pubmed/16912265]''' | |||
==== Other prostate cancer biomarkers ==== | |||
*See [[Prostate Cancer: Blood, Urine and Tissue-based markers]] | |||
* | |||
=== <span style="color:#ff0000">Imaging</span> === | === <span style="color:#ff0000">Imaging</span> === | ||
| Line 102: | Line 223: | ||
* '''<span style="color:#ff0000">Compared to DRE, TRUS does not improve the ability to stage prostate cancer</span>''' | * '''<span style="color:#ff0000">Compared to DRE, TRUS does not improve the ability to stage prostate cancer</span>''' | ||
* '''<span style="color:#ff0000">In general, TRUS under-stages rather than over-stages prostate cancer</span>''' | * '''<span style="color:#ff0000">In general, TRUS under-stages rather than over-stages prostate cancer</span>''' | ||
*Limited detection of transition zone lesions | |||
===== <span style="color:#ff0000"> | ===== <span style="color:#ff0000">Magnetic Resonance Imaging (MRI)</span> ===== | ||
* '''MRI | * See [https://www.youtube.com/watch?v=TfUt-Ai8DF4 Video on Approach and Principles to Prostate MRI] | ||
* ''' | *'''MRI uses strong magnetic fields and the electromagnetic properties of hydrogen protons to generate the signal that is used to create images[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503950/#]''' | ||
**Signal intensities vary based on the hydrogen content of the tissue | |||
**For details, see [https://pubmed.ncbi.nlm.nih.gov/16009826/ Pooley, Robert A.] "Fundamental physics of MR imaging." ''Radiographics'' 25.4 (2005): 1087-1099. | |||
====== <span style="color:#ff0000">Imaging sequences</span> ====== | ====== <span style="color:#ff0000">Imaging sequences</span> ====== | ||
* | * Sequences relevant for prostate imaging | ||
* | **T1-weighted imaging (T1WI) | ||
** | **T2-weighted imaging (T2WI) | ||
** | **Diffusion weighted imaging (DWI) with apparent diffusion coefficient (ADC) maps | ||
** '''<span style="color:#ff0000"> | **Dynamic contrast enhanced (DCE) imaging | ||
**Magnetic resonance spectroscopic imaging (MRSI) | |||
** '''<span style="color:#ff0000"> | *Multi-parametric (mpMRI) is the combination of multiple MRI sequences | ||
*'''<span style="color:#ff0000">In prostate cancer, the primary diagnostic parameters are (2):</span>[https://pubmed.ncbi.nlm.nih.gov/31392526/]''' | |||
**'''<span style="color:#ff0000">T2WI</span>''' | |||
**'''<span style="color:#ff0000">DWI with ADC maps</span>''' | |||
* '''<span style="color:#ff0000">T2WI</span>''' | * '''<span style="color:#ff0000">T2WI</span>''' | ||
** Captures the movement of protons in the xy-axis (transverse) | ** Captures the movement of protons in the xy-axis (transverse) | ||
** Primary | ** '''<span style="color:#ff0000">Primary uses (3):</span>''' | ||
** '''<span style="color:#ff0000">Optimal sequence to | **#'''<span style="color:#ff0000">Visualization of zonal and anatomical features of the prostate.</span>''' | ||
** ''' | **#*See [https://www.researchgate.net/figure/Zonal-prostate-anatomy-on-axial-T2-weighted-MRI-image-peripheral-zone-PZ-and_fig1_346570342 Figure] | ||
*** As 70% of all prostate cancers occur within the peripheral zone, the tissue characteristics allow for T2WI to detect a significant number of tumors in this zone | **#'''<span style="color:#ff0000">Optimal sequence in establishing the anatomic relation of the tumor with critical structures, such as the prostatic capsule and neurovascular bundles</span>'''.[https://pubmed.ncbi.nlm.nih.gov/26594835/] | ||
*** ''' | **#'''<span style="color:#ff0000">Optimal sequence to evaluate lesions in the transition zone[https://pubmed.ncbi.nlm.nih.gov/31392526/]</span>''' | ||
**** Post-biopsy hemorrhage can interfere with tumor detection, since areas of hemorrhage appear similar to | ** '''<span style="color:#ff0000">Signal intensity</span>''' | ||
** ''' | ***'''<span style="color:#ff0000">High intensity</span>''' | ||
** | ****'''<span style="color:#ff0000">Fluids (CSF, urine)</span>''' | ||
****'''<span style="color:#ff0000">Fat</span>''' | |||
****'''<span style="color:#ff0000">Normal peripheral zone (due to its high water content)</span>''' | |||
****'''<span style="color:#ff0000">Seminal vesicles</span>''' | |||
***'''Intermediate intensity''' | |||
****'''Central zone''' | |||
*****Clinical implication: differential diagnosis of intermediate/low intensity lesions on T2 at the base of prostate and paramedian includes central zone that is being pushed out by BPH nodules of transition zone or cancer | |||
***'''<span style="color:#ff0000">Low intensity (7): </span><span style="color:#0000ff">CHAPPSS</span>''' | |||
***#'''<span style="color:#ff0000">Prostate </span><span style="color:#0000ff">C</span><span style="color:#ff0000">ancer</span>''' | |||
***#*As 70% of all prostate cancers occur within the peripheral zone, the tissue characteristics allow for T2WI to detect a significant number of tumors in this zone | |||
***#* | |||
***#'''<span style="color:#0000ff">H</span><span style="color:#ff0000">emorrhage</span>''' | |||
***#*Post-biopsy hemorrhage can interfere with tumor detection[https://pubmed.ncbi.nlm.nih.gov/26594835/], since areas of hemorrhage appear similar to cancer on T2WI | |||
***#**If obtaining prostate MRI post-biopsy, a delay of 6-8 weeks after biopsy is recommended; but even with this delay, significant hemorrhage may be discovered, and, if present, the examination should be rescheduled[https://pubmed.ncbi.nlm.nih.gov/26594835/] | |||
***#*Can be distinguished from cancer with T1WI (hemorrhage has high intensity on T1WI, cancer has low intensity on T2WI) | |||
***#'''<span style="color:#0000ff">A</span><span style="color:#ff0000">trophy</span>''' | |||
***#'''<span style="color:#0000ff">P</span><span style="color:#ff0000">rostatitis</span>''' | |||
***#'''<span style="color:#0000ff">P</span><span style="color:#ff0000">ost-treatment changes</span>''' | |||
***#'''<span style="color:#0000ff">S</span><span style="color:#ff0000">cars</span>''' | |||
***#'''<span style="color:#0000ff">S</span><span style="color:#ff0000">tromal hyperplasia i.e. benign prostatic hyperplasia (BPH)</span>''' | |||
***#*'''Clinical implication: On T2WI, BPH nodules can be difficult to distinguish from cancer''' | |||
**Lesion shape | |||
***Wedge-shaped/linear lesions are more likely benign | |||
* '''<span style="color:#ff0000">Diffusion weighted imaging (DWI)</span>''' | * '''<span style="color:#ff0000">Diffusion weighted imaging (DWI)</span>''' | ||
** Measures the diffusion of water protons within tissue | ** '''Measures the diffusion of water protons within tissue''' | ||
** | ***'''In normal water-rich glandular tissue, protons are mobile''' | ||
** '''ADC values are calculated by the software and displayed as a parametric map reflecting the degree of diffusion of water molecules through different tissues.''' | ***'''In densely packed water-poor tissue such as that found in tumors, protons have restricted movement.''' | ||
*** | **Images are acquired by sequentially applying multiple magnetic field gradients, known as b-values, to calculate ADC values and construct ADC maps. | ||
*** '''Normal glandular prostate tissue | ***b-value is a factor that reflects the strength and timing of the gradients used to generate diffusion-weighted images. The higher the ''b''-value, the stronger the diffusion effects. | ||
** '''<span style="color:#ff0000">Tumors with the higher restriction (low ADC values) tend to be higher grade</span>''' | ****Typical ''b''-values available on modern MRI scanners range from 0 to about 4000 s/mm²[https://mriquestions.com/what-is-the-b-value.html] | ||
** '''<span style="color:#ff0000">Optimal sequence to | ***ADC values are calculated by the software and displayed as a parametric map reflecting the degree of diffusion of water molecules through different tissues. | ||
****Different b-values will produce different ADC maps | |||
****In general, ADC values decrease when b-values increase above 1000 s/mm²[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4730971/] | |||
**'''<span style="color:#ff0000">Primary use:</span>''' | |||
***'''<span style="color:#ff0000">Optimal sequence to evaluate lesions in the peripheral zone[https://pubmed.ncbi.nlm.nih.gov/31392526/]</span>''' | |||
**'''<span style="color:#ff0000">Signal intensity</span>''' | |||
***'''<span style="color:#ff0000">ADC maps</span>''' | |||
****'''Intermediate intensity''' | |||
*****'''Normal glandular prostate tissue allows unrestricted free water movement''' | |||
****'''<span style="color:#ff0000">Low intensity</span>''' | |||
*****'''<span style="color:#ff0000">Prostate cancer</span>[https://pubmed.ncbi.nlm.nih.gov/23878284/]''' | |||
******'''Appears as high signal intensity focus on high b-value images''' | |||
*******Image with highest b-value (lowest ADC) likely to be most useful | |||
******'''<span style="color:#ff0000">Tumors with the higher restriction (low ADC values) tend to be higher grade</span>''' | |||
*'''<span style="color:#ff0000">T1WI</span>''' | |||
** Captures the movement of protons in the z-axis | |||
** '''<span style="color:#ff0000">Primary uses (2):</span>''' | |||
**#'''<span style="color:#ff0000">Optimal sequence to identify areas of hemorrhage within the prostate</span>''' | |||
**#'''Often used to look at normal anatomical details.''' | |||
** '''<span style="color:#ff0000">Signal intensity</span>''' | |||
***'''<span style="color:#ff0000">High intensity</span>''' | |||
****'''<span style="color:#ff0000">Hemorrhage/blood has high signal intensity on T1</span>, against a homogenous low signal background.''' | |||
****'''<span style="color:#ff0000">Fat</span>''' | |||
***'''<span style="color:#ff0000">Low intensity''' | |||
****'''<span style="color:#ff0000">Fluids (CSF, urine)</span>''' | |||
****'''<span style="color:#ff0000">Prostate cancer''' | |||
* '''<span style="color:#ff0000">Dynamic contrast enhancement (DCE)</span>''' | * '''<span style="color:#ff0000">Dynamic contrast enhancement (DCE)</span>''' | ||
** | ** A series of T1WI obtained before, during, and after the injection of intravenous gadolinium-based contrast media | ||
*** Tumors have increased vascularity due to neo-angiogenesis and, therefore, take up the contrast agent more rapidly than normal tissue. Moreover, this contrast washes out of tumor regions quickly leading to a steep wash-in-wash-out enhancement curve. | **'''<span style="color:#ff0000">Primary use (1):</span>''' | ||
** | ***'''<span style="color:#ff0000">Measures the vascularity of prostate tissue</span>'''. | ||
**** '''Focal early hyperenhancement is suggestive of a malignancy''' | |||
*****Tumors have increased vascularity due to neo-angiogenesis and, therefore, take up the contrast agent more rapidly than normal tissue. Moreover, this contrast washes out of tumor regions quickly leading to a steep wash-in-wash-out enhancement curve. | |||
*****There is considerable overlap of with benign conditions, such as benign prostatic hyperplasia and prostatitis. | |||
******DCE MRI is most helpful when the T2W MRI and DWI are equivocal. | |||
*******In these cases, strong early enhancement or rapid washout of contrast media from the lesion increases the suspicion that the lesion is a clinically significant malignancy. | |||
****Very useful in detecting sites of recurrent prostate cancer after prostatectomy or radiation therapy where focal enhancement may indicate a site of focal recurrence | |||
* '''<span style="color:#ff0000">Magnetic resonance spectroscopic imaging (MRSI)</span>''' | * '''<span style="color:#ff0000">Magnetic resonance spectroscopic imaging (MRSI)</span>''' | ||
** '''Uses the relative concentration of cellular metabolites in the prostate, specifically citrate and choline, to detect prostate cancer.''' | ** '''Uses the relative concentration of cellular metabolites in the prostate, specifically citrate and choline, to detect prostate cancer.''' | ||
| Line 142: | Line 322: | ||
** '''<span style="color:#ff0000">When combined with T2WI, MRSI has been found to have the highest sensitivity of all MRI sequences (92%) in detecting prostate cancer.</span>''' | ** '''<span style="color:#ff0000">When combined with T2WI, MRSI has been found to have the highest sensitivity of all MRI sequences (92%) in detecting prostate cancer.</span>''' | ||
** While MRSI is a promising imaging sequence, it requires an extra 10 to 15 minutes of examination time. Also, for this phase an endorectal coil (see below) is mandatory at 1.5T and optional at 3T. For these reasons, MRSI is less commonly performed than other mpMRI sequences in prostate MRI studies. | ** While MRSI is a promising imaging sequence, it requires an extra 10 to 15 minutes of examination time. Also, for this phase an endorectal coil (see below) is mandatory at 1.5T and optional at 3T. For these reasons, MRSI is less commonly performed than other mpMRI sequences in prostate MRI studies. | ||
* ''' | * '''Bi-parametric MRI (bpMRI)''' | ||
** | ** '''Combination of only non-contrast T2WI and DWI (with ADC maps) series''' | ||
** | **Advantages[https://pubmed.ncbi.nlm.nih.gov/26594835/] | ||
***Can be performed without an endorectal coil | |||
***Can be performed intravenous access and contrast administration | |||
***Fewer sequences reduces time/costs to complete study | |||
****Requires less than half the in-bore magnet time to perform compared with the complete mpMRI | |||
**Disadvantages | |||
***Fewer imaging sequences which may limit adequate interpretation | |||
**'''No significant difference in sensitivity or specificity compared to mpMRI''' | |||
***Systematic review and meta-analysis (2018) | |||
****20 studies involving 2142 patients | |||
****Results | |||
*****No significant difference in pooled sensitivity and specificity | |||
******Sensitivity: 0.74 (95% CI, 0.66–0.81) bpMRI vs. 0.76 (95% CI, 0.69–0.82) mpMRI | |||
******Specificity: 0.90 (95% CI, 0.86–0.93) bpMRI vs. 0.89 (95% CI, 0.85–0.93) mpMRI | |||
****[https://pubmed.ncbi.nlm.nih.gov/30240296/ Woo, Sungmin, et al.] "Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis." ''American Journal of Roentgenology'' (2018): W226-W241. | |||
====== <span style="color:#ff0000">Magnet strength</span> ====== | ====== <span style="color:#ff0000">Magnet strength</span> ====== | ||
| Line 152: | Line 346: | ||
====== <span style="color:#ff0000">Endorectal coil</span> ====== | ====== <span style="color:#ff0000">Endorectal coil</span> ====== | ||
* '''Standard clinical field strengths of 1.5T do not provide sufficient signal-to-noise ratio for clinical diagnosis of prostate cancer. To compensate for this deficiency, the use of surface and/or endorectal coil arrays has been proposed | * '''Advantages''' | ||
* | **'''<span style="color:#ff0000">Improves image resolution by increasing the SNR</span>''' | ||
* | ***'''Standard clinical field strengths of 1.5T do not provide sufficient signal-to-noise ratio for clinical diagnosis of prostate cancer. To compensate for this deficiency, the use of surface and/or endorectal coil arrays has been proposed''' | ||
* '''There is consensus regarding the use of a surface body coil and an endorectal coil at 1.5T but controversy remains regarding the need for an endorectal coil at 3T.''' | ***'''There is consensus regarding the use of a surface body coil and an endorectal coil at 1.5T but controversy remains regarding the need for an endorectal coil at 3T.''' | ||
** '''<span style="color:#ff0000">The highest signal-to-noise ratio (SNR) is achieved at 3T with an endorectal coil</span> but acceptable results can be achieved at 3T without an endorectal coil.''' | **** '''<span style="color:#ff0000">The highest signal-to-noise ratio (SNR) is achieved at 3T with an endorectal coil</span> but acceptable results can be achieved at 3T without an endorectal coil.''' | ||
*Disadvantages | |||
**Patient discomfort | |||
**Additional time required for proper placement and verification | |||
**Cost | |||
**Deformation of the gland which may affect the image registration for targeted biopsy or radiation planning | |||
***Concerns regarding alterations in prostate volume have largely been dispelled. | |||
====== <span style="color:#ff0000">Prostate Imaging and Reporting Archiving Data System (PI-RADS) ====== | ====== <span style="color:#ff0000">Prostate Imaging and Reporting Archiving Data System (PI-RADS) ====== | ||
* '''Provides guidance for interpretation of different sequences and prostate zones''' | * '''Provides guidance for interpretation of different sequences and prostate zones''' | ||
*''' | *Introduced in 2012, revised in 2015 (version 2.0) | ||
**'''<span style="color:#ff0000">Positive predictive values ISUP grade group ≥2 based on PI-RADS score:</span>[https://pubmed.ncbi.nlm.nih.gov/35393568/]''' | *'''Each lesion is scored, using a 5-point scale based on the likelihood (probability) that mpMRI findings correlate with the presence of a clinically significant cancer''' | ||
**Clinically significant cancer is defined on pathology/histology as (3):[https://pubmed.ncbi.nlm.nih.gov/26427566/] | |||
**#Gleason score ≥7 (including 3+4 with prominent but not predominant Gleason 4 component) and/or | |||
**#Volume ≥0.5cc and/or | |||
**#Extra prostatic extension(EPE). | |||
**'''Detection rates by PI-RADS score for any prostate cancer[https://pubmed.ncbi.nlm.nih.gov/37096582/]''' | |||
*** '''PR 1-2: 15%''' | |||
*** '''PR 3: 25%''' | |||
*** '''PR 4: 58%''' | |||
*** '''PR 5: 85%''' | |||
**'''<span style="color:#ff0000">Positive predictive values for ISUP grade group ≥2 based on PI-RADS score:</span>[https://pubmed.ncbi.nlm.nih.gov/35393568/]''' | |||
***'''<span style="color:#ff0000">PI-RADS 1-2: 7%[https://pubmed.ncbi.nlm.nih.gov/37096582/]</span>''' | |||
***'''<span style="color:#ff0000">PI-RADS 3: 12–15%</span>''' | ***'''<span style="color:#ff0000">PI-RADS 3: 12–15%</span>''' | ||
***'''<span style="color:#ff0000">PI-RADS 4: 39–48%</span>''' | ***'''<span style="color:#ff0000">PI-RADS 4: 39–48%</span>''' | ||
***'''<span style="color:#ff0000">PI-RADS 5: 72%</span>''' | ***'''<span style="color:#ff0000">PI-RADS 5: 72%</span>''' | ||
**If PIRADS[https://pubmed.ncbi.nlm.nih.gov/26427566/] | |||
***≥4 or 5, biopsy should be considered | |||
***≤3, biopsy may or may not be appropriate, depending on factors other than mpMRI alone | |||
* Lesions in the peripheral zone appear round or irregular, and are focally hypointense, whereas transition zone lesions are non-circumscribed and moderately hypointense, and may exhibit a characteristic ‘‘erased charcoal’’ sign. | * Lesions in the peripheral zone appear round or irregular, and are focally hypointense, whereas transition zone lesions are non-circumscribed and moderately hypointense, and may exhibit a characteristic ‘‘erased charcoal’’ sign. | ||
| Line 227: | Line 441: | ||
* '''Availability/cost''' | * '''Availability/cost''' | ||
* '''Interobserver reproducibility remains a challenge.''' | * '''Interobserver reproducibility remains a challenge.[https://pubmed.ncbi.nlm.nih.gov/32315265/]''' | ||
* '''Learning curve related to reading and to performing fusion biopsies''' | * '''Learning curve related to reading MRI and to performing fusion biopsies''' | ||
* '''Use of MRI for tumor staging remains controversial.''' | * '''Use of MRI for tumor staging remains controversial.''' | ||
**Variable sensitivities (13-91%) and specificities (49-97%) have been reported for predicting extra-capsular extension. | **Variable sensitivities (13-91%) and specificities (49-97%) have been reported for predicting extra-capsular extension. | ||
====== Guidelines on Use of MRI ====== | ====== Guidelines on Use of MRI Before Biopsy ====== | ||
* ''' | * '''2023 AUA Guidelines on Early Detection of Prostate Cancer''' | ||
**'''Multiparametric MRI is strongly recommended, if available | **'''<span style="color:#ff0000">May be used prior to initial biopsy to increase the detection of GG2+ prostate cancer[https://pubmed.ncbi.nlm.nih.gov/23659877/]</span>''' | ||
***It is reasonable to obtain an mpMRI in biopsy-naïve patients prior to their first biopsy, but such a practice cannot be regarded as the standard approach based on the currently available evidence. | |||
*'''2023 NCCN (PROSD-3)''' | |||
**'''Multiparametric MRI is strongly recommended, if available''' | |||
*'''2022 EAU[https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation]''' | *'''2022 EAU[https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation]''' | ||
**'''Systematic biopsy is an acceptable approach in case MRI is unavailable''' | **'''Systematic biopsy is an acceptable approach in case MRI is unavailable''' | ||
| Line 300: | Line 517: | ||
* '''≈10%''' (but up to 20%) '''of negative MRI have clinically significant prostate cancer''' | * '''≈10%''' (but up to 20%) '''of negative MRI have clinically significant prostate cancer''' | ||
* '''Predictors of clinically significant prostate cancer in presence of negative MRI''' | * '''Predictors of clinically significant prostate cancer in presence of negative MRI[https://pubmed.ncbi.nlm.nih.gov/31967522/]''' | ||
** PSA density > 0.15 ng/ml/cc[https://pubmed.ncbi.nlm.nih.gov/30189186/][https://pubmed.ncbi.nlm.nih.gov/33080153/] | ** PSA density > 0.15 ng/ml/cc[https://pubmed.ncbi.nlm.nih.gov/30189186/][https://pubmed.ncbi.nlm.nih.gov/33080153/] | ||
** History of previous negative biopsy[https://pubmed.ncbi.nlm.nih.gov/30189186/] | ** History of previous negative biopsy[https://pubmed.ncbi.nlm.nih.gov/30189186/] | ||
** | ** Abnormal DRE[https://pubmed.ncbi.nlm.nih.gov/33080153/]/Clinical stage T2a or greater[https://pubmed.ncbi.nlm.nih.gov/33080153/] | ||
** Prostate cancer family history[https://pubmed.ncbi.nlm.nih.gov/33080153/] | ** Prostate cancer family history[https://pubmed.ncbi.nlm.nih.gov/33080153/] | ||
| Line 314: | Line 530: | ||
==== <span style="color:#ff0000">Metastasis</span> ==== | ==== <span style="color:#ff0000">Metastasis</span> ==== | ||
===== "Conventional" imaging ===== | |||
* '''<span style="color:#ff0000">Regional</span>''' | |||
** '''<span style="color:#ff0000">CT/MRI is used for regional lymph node staging</span>''' | |||
* '''<span style="color:#ff0000">Distant</span>''' | |||
** '''<span style="color:#ff0000">Radionuclide bone scan (bone scintigraphy) is the most commonly used test for the detection of skeletal metastases</span>''' | |||
===== Novel Positron Emission Tomography (PET)-CT imaging[https://pubmed.ncbi.nlm.nih.gov/33661093/] ===== | |||
* '''PET scans use a radioactive tracer to show both normal and abnormal metabolic activity.''' | |||
*** | **Use of either hybrid PET/computed tomography (CT) or PET/magnetic resonance (MR) scanners with PSMA-targeted radiopharmaceuticals allows anatomical localization and characterization of PSMA-avid lesions | ||
** ''' | *'''<span style="color:#ff0000">Advantage over conventional imaging</span>''' | ||
* | ** '''<span style="color:#ff0000">Higher sensitivity for the detection of prostate cancer recurrence and metastases at low PSA values (<2.0ng/mL).</span>''' | ||
*** 38% of PSMA-targeted PET scans show disease sites in males with PSA <0.5 ng/ml[https://pubmed.ncbi.nlm.nih.gov/30850500/] | |||
** | **'''<span style="color:#ff0000">18F-PET provides the best sensitivity and specificity for the detection of bony metastases in prostate cancer</span>''' | ||
====== Prostate cancer PET radiopharmaceutical tracers ====== | |||
* '''<span style="color:#ff0000">Not PSMA-specific radiopharmaceutical tracers''' | |||
** Examples include '''<span style="color:#ff0000">18F-fluciclovine (trade name Axumin)</span>''', 18F-fluorodeoxyglucose (FDG), and 11C-choline | |||
*** 18F-fluciclovine FDA approved in 2016 | |||
** '''Replaced by PSMA-specific tracers''' | |||
*** '''Lower sensitivity and specificity than PSMA-specific ligands''' | |||
**** In a 2019 prospective study of males who had undergone prostatectomy and had a rising PSA still under 2.0ng/mL, 68Ga-PSMA-PET detected occult metastases 4.54x significantly more frequently than 18F-fluciclovine-PET[https://pubmed.ncbi.nlm.nih.gov/31375469/] | |||
* '''<span style="color:#ff0000">PSMA-specific radiopharmaceuticals tracers</span>''' | |||
** '''PET tracers that bind to Prostate-Specific Membrane Antigen (PSMA)''' | |||
*** '''PSMA''' | |||
**** Also known as glutamate carboxypeptidase II (GCP II) | |||
****** | **** A transmembrane glycoprotein | ||
**** '''Highly overexpressed in >90% of prostate cancers''' | |||
***** Increased expression with | |||
****** Increased pathological Gleason grade | |||
****** Castrate-resistance | |||
** '''<span style="color:#ff0000">PSMA-specific radiopharmaceutical tracers used in prostate cancer (2):</span>''' | |||
***'''<span style="color:#ff0000">Fluorine-18 (18F)-labeled PSMA-specific</span>''' (18F-DCFPyL ('''piflufolastat''' F 18) (trade name '''<span style="color:#ff0000">Pylarify</span>'''), 18F-PSMA-1007) | |||
****'''Most commonly used radiotracer in the US and''' (18F-DCFPyL) '''Canada''' | |||
****18F-DCFPyL adverse reactions: headache, altered taste, fatigue[https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer] | |||
***'''<span style="color:#ff0000">Gallium-68 (68Ga)-labeled PSMA-specific</span>''' | |||
****'''High specificity and sensitivity''' | |||
*****'''Outperforms standard CT and MRI in detection of nodal and osseous metastases.''' | |||
****As of May 2021, only available locally at two sites in California[https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer] | |||
****'''Excretion: urinary''' | |||
**'''<span style="color:#ff0000">Uptake of PSMA-specific radiopharmaceuticals</span>[https://pubmed.ncbi.nlm.nih.gov/33661093/]''' | |||
***'''<span style="color:#ff0000">Physiological</span>''' | |||
****'''<span style="color:#ff0000">High uptake: lacrimal and salivary glands, kidneys</span>''' | |||
****'''<span style="color:#ff0000">Moderate uptake: spleen, nasopharynx</span>''' | |||
**** '''Variable uptake: vocal cords, trachea, bronchi, proximal GI tract''' | |||
**** '''Uptake also seen in central nervous system and peripheral nervous system''' (ganglia and nerve routes) | |||
***** Celiac and stellate ganglia may be false-positives for retroperitoneal and supraclavicular lymphadenopathy | |||
*** '''<span style="color:#ff0000">Benign disease</span>''' | |||
***# '''<span style="color:#ff0000">Infectious and inflammatory processes</span> (e.g., sarcoidosis)''' | |||
***#* Increased blood flow and vascular permeability may partly explain the increased PSMA uptake in inflammatory conditions. | |||
***# '''<span style="color:#ff0000">Benign neoplasms</span>''' (mesenchymal tumors (vascular, neurogenic, connective tissue origin) and epithelial tumors (edenoma and thymoma)) | |||
***# '''<span style="color:#ff0000">Bone remodelling</span>''' (healing fractures, degenerative or arthritic processes (e.g., osteophytes), Paget's disease) | |||
***# '''<span style="color:#ff0000">Amyloidosis</span>''' | |||
*** '''<span style="color:#ff0000">Malignancy</span>''' | |||
**** '''<span style="color:#ff0000">Prostate cancer</span>''' | |||
**** '''<span style="color:#ff0000">Non-prostate malignancies</span>''' | |||
***** '''<span style="color:#ff0000">Renal cell carcinoma</span>,''' leiomyosarcoma, thyroid cancer, nasopharyngeal cancer, GI tract cancer, breast cancer, neuroendocrine cancer | |||
***** | ** '''<span style="color:#ff0000">Clearance of PET tracers used in prostate cancer</span>[https://pubmed.ncbi.nlm.nih.gov/33661093/]''' | ||
*** '''<span style="color:#ff0000">Most are cleared via the urinary tract</span>, with high accumulation in the urinary tract and bladder and moderate uptake in the liver''' | |||
**** '''Exception: 18F-PSMA-1007, 18F-fluciclovine, and 11-choline</span> are cleared primarily by the hepatobiliary tract, with higher uptake in the liver, and little accumulation in the ureters and bladder''' | |||
***** '''<span style="color:#ff0000">Clinical implication: since 18F-PSMA-1007, 18F-fluciclovine, and 11-choline have minimal excretion from the urinary tract, use of these tracers may aid in identifying disease sites adjacent to the bladder and ureters, such as local tumor recurrence after prostatectomy.</span>''' | |||
** '''<span style="color:#ff0000">Causes of false-negative PSMA-targeted PET</span>''' | |||
**# '''<span style="color:#ff0000">Small tumor volume</span>''' | |||
**#* May be seen in early-stage biochemical recurrence when the serum PSA <0.5 ng/ml | |||
**# '''<span style="color:#ff0000">Neuroendocrine differentiation of prostate cancer</span>''' with downregulation of PSMA expression | |||
**#* Neuroendocrine differentiation occurs in 5–10% of prostate cancers overall and approximately 30% of men with advanced disease | |||
**# '''<span style="color:#ff0000">Androgen receptor inhibition</span>''' | |||
* | **#* '''Short-term ADT likely increases PSMA-targeted PET positivity, whereas prolonged, continuous ADT is associated with a higher likelihood of a negative PSMA-targeted PET''' | ||
** | |||
*** | ====== Potential roles of PSMA-PET imaging in prostate cancer ====== | ||
**** | |||
****# ''' | # '''<span style="color:#ff0000">Primary staging of high-risk prostate cancer</span>''' | ||
#* '''<span style="color:#ff00ff">proPSMA (2020)</span>''' | |||
#**Objective: determine whether PSMA PET-CT prior to treatment in patient with high risk prostate cancer increases detection of metastases, compared to conventional imaging | |||
#**'''Population: 300 males with high-risk (PSA ≥20, grade group ≥3, or ≥cT3) prostate cancer being considered for radical prostatectomy or radiotherapy''' | |||
**** | #**'''Randomized to Ga-PSMA-11 PET-CT vs. conventional imaging (CT and bone scan), followed by second-line cross-over imaging.''' | ||
*** | #***Second-line cross-over imaging was done within 14 days of baseline imaging, unless ≥3 distant metastases identified on first-line imaging. | ||
**** | #***At 6 months, patients underwent repeat imaging as per randomised group with cross-over if | ||
**** | #****Baseline imaging evidence of metastasis (N1 or M1) | ||
****# | #****Biochemical or clinical suspicion of residual or recurrent disease. | ||
**''' | #***'''Primary outcome: accuracy (based on area under the curve (AUC)) of first-line imaging at identifying either pelvic nodal or distant metastatic disease, compared to assessment of metastases at 6 months (reference standard)''' | ||
***''' | #****Metastatic disease disease was defined by hard and soft criteria based on histopathologic, imaging, clinical, and biochemical findings. | ||
#***'''Results:''' | |||
***** | #****'''Primary outcome: accuracy (based on AUC) significantly improved with PSMA PET-CT compared to conventional imaging (absolute difference: 27%, 92% PSMA PET-CT vs. 65% conventional imaging)''' | ||
***** | #*****Sensitivity: 85% PSMA PET-CT vs. 38% conventional imaging | ||
#*****Specificity: 98% PSMA PET-CT vs. 91% conventional imaging | |||
****** | #***** PSMA PET-CT more sensitive and specific than conventional imaging for both pelvic nodal or distant metastases | ||
***** | #**** '''Secondary outcomes:''' | ||
****** | #***** '''Change in management more common with PSMA PET-CT (28% PSMA PET-CT vs. 15% conventional imaging)''' | ||
*** | #***** Less equivocal findings with PSMA PET-CT | ||
#***** Radiation exposure reduced with PSMA PET-CT (8 mSv PSMA PET-CT vs. 19 mSv conventional imaging) | |||
#*** Limitations: | |||
#****Lack of histopathological evidence of metastasis in majority of cases; unclear validity of reference standard used in this study | |||
** | #*****Only 23% of positive cases (pelvic nodal or distant metastasis) met "hard" criteria to define metastasis (true positive). | ||
** | #******Hard criteria were histopathology showing prostate adenocarcinoma, or change of a bone lesion to sclerotic or blastic on follow-up imaging. | ||
#*** [https://pubmed.ncbi.nlm.nih.gov/32209449/ Hofman, Michael S., et al.] "Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study." ''The Lancet'' 395.10231 (2020): 1208-1216. | |||
#** '''Clinical implications (2):''' | |||
#**# '''PSMA PET/CT may identify nodes outside of the routine surgical field, as well as additional sites of distant disease''' | |||
#**# '''Sensitivity of PSMA PET/CT in detecting nodal disease not high enough to avoid treatment of lymph nodes''' in patients with risk of lymph node involvement | |||
* | # '''<span style="color:#ff0000">Improved quantification of metastatic burden</span>''' | ||
* | #* '''Oligometastatic disease may be identified, and such patients may be offered management in clinical trials or metastasis-directed surgery.''' | ||
# '''<span style="color:#ff0000">Staging of biochemical recurrence</span>''' | |||
* | #* '''Most common indication for PSMA-targeted PET''' | ||
* | #* '''Management of biochemical recurrence depends on disease extent:''' local recurrence of local recurrence with regional nodal metastases vs. distant metastatic disease | ||
# '''<span style="color:#ff0000">Determining patient suitability for PSMA-targeted radionuclide therapy</span>''' | |||
#* '''Both 177Lu and 225Ac PSMA-targeted radioligand therapy are emerging as promising therapies for castration-resistant disease.''' | |||
# '''<span style="color:#ff0000">Primary detection of tumor as an adjunct to multiparametric MRI</span>''' | |||
#* Role of PSMA-targeted PET as an adjunct to mpMRI for primary detection of clinically significant prostate cancer is not well-established | |||
* | |||
====== Indications ====== | |||
** | * '''<span style="color:#ff0000">FDA approved for (2)</span>[https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-second-psma-targeted-pet-imaging-drug-men-prostate-cancer]''' | ||
***** | *# '''<span style="color:#ff0000">To identify metastases, not demonstrated on conventional imaging, that are potentially curable by surgery or other therapy</span>''' | ||
****** | *# '''<span style="color:#ff0000">After biochemical recurrence, to evaluate for role of locoregional salvage treatment</span>''' | ||
* '''<span style="color:#ff0000">2021 CUA Best Practice Report Recommendations for PSMA PET/CT</span>[https://pubmed.ncbi.nlm.nih.gov/33661093/]''' | |||
** | ** '''<span style="color:#ff0000">PSMA-targeted PET may be helpful (3)</span>''': | ||
**# '''<span style="color:#ff0000">To identify clinically significant prostate cancer when systematic biopsies and MRI are negative</span>''' | |||
**#* Recommendation strength = 4 where "Strength of recommendation: 1=strong; 2=moderate; 3=weak." | |||
**# '''<span style="color:#ff0000">To identify metastases, not demonstrated on conventional imaging, that may influence management</span>''' | |||
**## Primary staging of high-risk prostate cancer | |||
**## Castration-sensitive prostate cancer (confirm oligometastatic vs. extensive disease) | |||
**##* In metastatic, hormone-sensitive prostate cancer, docetaxel has level 1 evidence in males with high-volume disease, defined as visceral metastasis or ≥4 bone metastases with ≥ 1 beyond the vertebral bodies and pelvis | |||
**## Non-metastatic, castrate-resistant prostate cancer | |||
**##* If metastatic, consider systemic therapy | |||
**# '''<span style="color:#ff0000">After biochemical recurrence, to evaluate for role of locoregional salvage treatment</span>''' | |||
*'''<span style="color:#ff0000">Unknown if adoption of PSMA-PET resulting in improved staging of high-risk or after biochemical recurrence will result in improved overall survival.</span>''' | |||
** Impact of PSMA-targeted PET on management ranged from 30–76%; modifications made to pre-PSMA-targeted PET planned management included avoidance of systemic therapy (19–50%) and PET-directed local therapy in up to 60% of cases[https://pubmed.ncbi.nlm.nih.gov/30850500/] | |||
=== Other === | === Other === | ||
==== | ==== Transrectal Ultrasound (TRUS) Biopsy ==== | ||
* Concept: improve prediction models by combining variables | * Patients with clinical indications to confirm diagnosis of prostate cancer undergo TRUS biopsy | ||
* '''Most widely | * '''Biopsy threshold''' | ||
** [https://pubmed.ncbi.nlm.nih.gov/23659877/ '''2023 AUA Guidelines on Early Detection of Prostate Cancer'''] | |||
***'''<span style="color:#ff0000">May be tailored for select patients, similar to risk-stratified re-screening intervals</span>''' | |||
****'''For patients with BRCA mutations, biopsy referral threshold should be 3 ng/mL''' | |||
***'''<span style="color:#ff0000">Clinicians and patients may use validated risk calculators to inform the SDM process regarding prostate biopsy</span>''' | |||
****Pre-biopsy Risk Calculators | |||
***** Concept: improve prediction models by combining variables | |||
***** [https://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators '''ERSPC'''] | |||
*****[https://riskcalc.org/PCPTRC/ '''PCPT V2'''] | |||
*****[https://riskcalc.org/PBCG/ '''PBCG'''] | |||
******'''In one study, investigators compared PBCG with PCPT and concluded that PCPT performed better in minority groups.''' | |||
***PSA velocity should not be used as sole indication for secondary biomarker, imaging, or a biopsy. | |||
***'''Adjunctive urine or serum markers may be used when further risk stratification would influence the decision regarding whether to proceed with biopsy.''' | |||
****Several blood and urine markers are available, alone or in combination, to further risk stratify patients with a mildly elevated PSA, typically between 2.5 and 10 ng/mL. | |||
*****'''Serum based''' | |||
******'''Percent free PSA''' | |||
*******Most widely available adjunctive test | |||
*******Lower percent free PSA is associated with greater likelihood of identifying prostate cancer on biopsy. | |||
******'''PSA density''' | |||
*******Higher PSA density (serum PSA [ng/mL] divided by imaging measures of prostate volume [cc]) is associated with the risk of identifying clinically significant prostate cancer on biopsy | |||
*******The Panel recognizes the continuous nature of risk associated with the spectrum of PSA density values and cautions against use of threshold values in isolation | |||
******4Kscore | |||
******IsoPSA | |||
******Proclarix | |||
******PHI | |||
******STHLM-3 | |||
*****'''Urine based''' | |||
******Post-DRE Urine | |||
*******PCA3 | |||
*******MPS | |||
*******SelectMDx | |||
*******TMPRSS:ERG | |||
******Urine | |||
*******ExoDx Prostate Intelliscore | |||
*******MiR Sentinel | |||
******Tissue | |||
*******Confirm MDx | |||
*****Such tests may be of value among patients with modestly elevated PSA tests, especially in patients with a prior negative biopsy in whom PSA alone is not recommended as the sole trigger for rebiopsy. | |||
*** '''When the risk of clinically significant prostate cancer is sufficiently low based on available clinical, laboratory, and imaging data, clinicians and patients may forgo near-term prostate biopsy.''' | |||
***<span style="color:#ff0000">'''Role of prostate biopsy in very elevated PSA'''</span> | |||
****'''<span style="color:#ff0000">If PSA > 50 ng/mL </span>'''(and no clinical concerns for infection or other cause for increased PSA (e.g., recent prostate instrumentation)), '''<span style="color:#ff0000">may omit a prostate biopsy in cases if (2):</span>''' | |||
*****'''<span style="color:#ff0000">Biopsy poses significant risk (e.g., anticoagulation, significant comorbidity, frailty)</span>''' | |||
*****'''<span style="color:#ff0000">Need for prostate cancer treatment is urgent (e.g., impending spinal cord compression from metastases)</span>''' | |||
****Imaging to establish extent of disease or confirm metastasis may be helpful if an immediate biopsy is not performed. | |||
***'''If MRI performed prior to biopsy''' | |||
****'''<span style="color:#ff0000">If no abnormal lesions on prostate MRI but concern for elevated risk for GG2+ prostate cancer, proceed with a systematic biopsy.</span>''' | |||
*****≈1 in 10 patients who have a negative prostate MRI may have GG2+ cancer on biopsy, | |||
******Negative predictive value (NPV) of a “negative” MRI (defined as PIRADS 1 to 2) to detect GG2+ prostate cancer among biopsy-naïve patients was 91%. | |||
*****A systematic biopsy should include a minimum of 12 cores | |||
*****Various templates employing these principles exist for transrectal and transperineal approaches. | |||
****'''<span style="color:#ff0000">For biopsy-naïve patients with abnormal lesions on prostate MRI, perform targeted biopsies and may also perform a systematic template biopsy.</span>''' | |||
*****Adding a systematic biopsy to the target only approach | |||
******Advantage: | |||
*******Optimizes cancer yield, potentially finding more GG2+ cancer | |||
********Incremental yield of off-target biopsy samples may be influenced by the sampling error associated with software image registration at targeted biopsy | |||
******Disadvantages: | |||
*******Potentially finding more GG1 cancer | |||
*******May increase patient discomfort and other biopsy-associated complications due to larger number of cores | |||
***'''Repeat biopsy[https://pubmed.ncbi.nlm.nih.gov/23659877/]''' | |||
****'''<span style="color:#ff0000">If prostate biopsy demonstrates</span>''' | |||
*****'''<span style="color:#ff0000">Malignancy: discuss [[Management of Localized Prostate Cancer]]</span>''' (+/- staging studies, if applicable) | |||
*****'''<span style="color:#ff0000">High-grade Prostatic Intraepithelial Neoplasia</span>''' | |||
******'''<span style="color:#ff0000">If focal (one core): should not perform immediate repeat biopsy.</span>''' | |||
*******Risk of any cancer detected (not just high-grade) in subsequent biopsies is 20-30%, which is the same risk following an initial benign biopsy. | |||
******'''<span style="color:#ff0000">Multifocal: may proceed with additional risk evaluation.</span>''' | |||
*******Risk of GG2+ detection in repeat biopsies of patients with multifocal HGPIN is ≈30%, which is not higher than in those without this finding. | |||
*******Repeat biopsy after multifocal HGPIN should be based on PSA and DRE evolution, and mpMRI findings. | |||
*****'''<span style="color:#ff0000">Atypia</span>''' | |||
******'''<span style="color:#ff0000">Atypical small acinar proliferation (ASAP): should perform additional testing.</span>''' | |||
*******ASAP alone on needle biopsy is associated with a 30-50% risk of prostate cancer detection on repeat biopsy, with ≈10-20% of these being GG2+. | |||
*******Additional testing may include repeat systematic needle biopsy with consideration of mpMRI +/- targeted biopsy, PSA, and biomarkers (serum- or urine-based) | |||
******'''<span style="color:#ff0000">Atypical intraductal proliferation (AIP): should perform additional testing.</span>''' | |||
*******AIP describes lesions with greater architectural complexity and/or cytologic atypia than would be expected in HGPIN but lacking definitive criteria for the diagnosis of intraductal carcinoma (IDC-P). AIP encompasses many of the lesions formerly designated cribriform HGPIN, exhibiting loose cribriform architecture with moderate cytologic atypia, but lacking marked pleomorphism or necrosis. | |||
*******AIP, as either the sole finding or together with GG1 cancer only, warrants additional testing, which may include early repeat systematic needle biopsy or MRI +/- targeted biopsy. The timing of additional testing should be based on reassessment of risk | |||
*****'''<span style="color:#ff0000">Negative: reassess risk of undetected or future development of GG2+ disease</span>''' | |||
******'''<span style="color:#ff0000">At the time of re-evaluation after negative biopsy, clinicians should use a risk assessment tool that incorporates the protective effect of prior negative biopsy.</span>''' | |||
*******The guideline recommends utilizing validated risk calculators, particularly calculators that incorporate previous negative biopsy and mpMRI use in the repeat biopsy setting. | |||
********[https://www.prostatecancer-riskcalculator.com/seven-prostate-cancer-risk-calculators ERSPC] | |||
********[https://riskcalc.org/PCPTRC/ PCPT V2] | |||
********[https://riskcalc.org/PBCG/ PBCG] | |||
*******PSA level alone should not be used to decide whether to repeat the prostate biopsy in patients with a previous negative biopsy. | |||
******'''<span style="color:#ff0000">Based on risk assessment, SDM whether to</span>''' | |||
*******'''<span style="color:#ff0000">Discontinue screening</span>''' | |||
********'''Screening should not be discontinued based solely on a negative prostate biopsy.''' | |||
*******'''<span style="color:#ff0000">Continue screening</span>''' | |||
********If continuing screening after a negative biopsy, patient should be re-evaluated within the normal screening interval (2-4 years) or sooner, depending on risk of clinically significant prostate cancer and life expectancy. | |||
*******'''<span style="color:#ff0000">Perform adjunctive testing for early reassessment of risk.</span>''' | |||
********If concern remains elevated for GG2+ based on PSA density, previous MRI findings, or other factors, consider adjunctive testing (blood, urine, or tissue tests), or MRI (if not previously performed) to further risk stratify the patient if results are likely to influence the decision regarding repeat biopsy or otherwise substantively change the patient’s management. | |||
*********'''Biomarker testing''' | |||
**********After a negative initial biopsy in patients with low probability for harboring GG2+ prostate cancer, clinicians should not reflexively perform biomarker testing. | |||
***********In patients with a negative biopsy, with low probability for GG2+ disease, it is unlikely that additional biomarker tests will be informative. | |||
**********ConfirmMDx | |||
***********The only tissue-based biomarker assessing epigenetic changes in GSTP1, APC, RASSF1 in negative biopsy tissue | |||
***********Developed in the MATLOC study and validated in the DOCUMENT study to detect any prostate cancer and not specifically for GG2+ disease. | |||
**********Unclear how to integrate the use of these tests with mpMRI in prostate cancer early detection. | |||
**********It is imperative clinicians are familiar with biomarkers, understand what information or data each test provides, and consider whether additional information will impact management decisions before ordering a test. | |||
*********'''<span style="color:#ff0000">MRI prior to repeat biopsy</span>''' | |||
**********'''<span style="color:#ff0000">In patients undergoing repeat biopsy with no prior prostate MRI, a prostate MRI should be obtained prior to biopsy.</span>''' | |||
**********'''<span style="color:#ff0000">In patients with indications for a repeat biopsy who</span>''' | |||
***********'''<span style="color:#ff0000">Do not have a suspicious lesion on MRI, may proceed with a systematic biopsy.</span>''' | |||
************Factors that may identify patients likely to have clinically significant prostate cancer after a negative biopsy and a negative MRI include | |||
*************PSA density > 0.15 ng/mL | |||
*************PHI density value > 0.44 | |||
*************PSA velocity of ≥0.27 ng/mL/year | |||
***********'''<span style="color:#ff0000">Have a suspicious lesion on MRI, should perform targeted biopsies of the suspicious lesion and may also perform a systematic template biopsy.</span>''' | |||
************Ultimately, the decision to perform systematic sampling in addition to target sampling should be based on an integrated evaluation of MRI factors such as quality and confidence in target presence and clinical factors such as PSA, technique of initial biopsy, and time since prior systematic biopsy. | |||
*'''The choice of a PSA threshold for recommending a prostate biopsy is controversial'''. | |||
** Historically, many would recommend prostate biopsy once a patient’s serum PSA level is >4.0 ng/mL. However, '''data from the Prostate Cancer Prevention Trial demonstrated an overall prostate cancer detection rate of 15% for all men with a PSA level < 4.0 ng/mL and nearly 15% having a Gleason score of 7 or greater, suggesting no absolute safe threshold.''' | |||
==== Genetic testing ==== | ==== Genetic testing ==== | ||
* Germline mutations are inherited from parents; all cells have the mutation except red blood cells | * Germline mutations are inherited from parents; all cells have the mutation except red blood cells | ||
*Somatic mutations are acquired | *Somatic mutations are acquired | ||
==== | ===== Indications ===== | ||
* | |||
* ''' | ====== AUA ====== | ||
** ''' | * '''[https://pubmed.ncbi.nlm.nih.gov/35536144/ 2022 AUA Guidelines on Clinically Localized Prostate Cancer]''' | ||
*** | ** '''<span style="color:#ff0000">Recommended (5):''' | ||
** ''' | **# '''<span style="color:#ff0000">Ashkenazi Jewish ancestry''' | ||
*** | **#* '''Particularly in patients with Grade Group 2 or higher disease''' | ||
** | **# '''<span style="color:#ff0000">Known family history of familial cancer risk mutation''' | ||
**#* '''Examples: BRCA1, BRCA2, ATM, Lynch-syndrome associated genes''' | |||
**# '''<span style="color:#ff0000">Strong personal or family history of related cancers''' | |||
**#* '''Examples: breast, colorectal, ovarian, pancreatic, upper tract urothelial carcinoma''' | |||
**# '''<span style="color:#ff0000">Strong family history of prostate cancer''' | |||
**#* '''Examples: first-degree relative or multiple second-degree relatives diagnosed with Grade Group 2 or higher prostate cancer, particularly at early age (< 60 years), particularly if metastatic or lethal''' | |||
**# '''<span style="color:#ff0000">Adverse tumor characteristics''' | |||
**#* '''Examples: High-risk disease; intermediate-risk disease with intraductal or cribriform morphology''' | |||
====== NCCN ====== | |||
*'''NCCN (version 2.2021)''' | |||
** '''<span style="color:#ff0000">Recommended (5):''' | |||
**# '''<span style="color:#ff0000">Ashkenazi Jewish ancestry''' | |||
**#'''<span style="color:#ff0000">Positive family history of high-risk germline mutations (e.g. BRCA 1/2, Lynch syndrome)''' | |||
**#* '''BRCA-cancers (5): breast, ovarian, pancreatic, prostate, melanoma''' | |||
**#* '''Lynch syndrome cancers: (8) colonic (most common), endometrial (second most common), prostate, urothelial, adrenal, gastric, pancreatic, uterine, ovarian, and sebaceous carcinomas''' | |||
**#'''<span style="color:#ff0000">Personal history of breast cancer''' | |||
**#'''<span style="color:#ff0000">Metastatic (distant or regional (node-positive) prostate cancer''' | |||
**# '''<span style="color:#ff0000">High- or very-high risk localized prostate cancer''' | |||
** '''Optional (2)''' | |||
**# '''Intermediate-risk with intraductal or cribiform histology''' | |||
**# '''Personal history of colorectal, gastric, melanoma, upper tract urothelial, glioblastoma, biliary tract, or small intestine''' | |||
==== Stockholm-3 (STHLM-3) ==== | |||
*Multiplex test combining | |||
**Clinical variables (age, first-degree family history of prostate cancer, and previous biopsy) | |||
**Blood biomarkers (total PSA, free PSA, ratio of free to total PSA, hK2, MIC-1, and MSMB) | |||
**Polygenic risk score (PRS) | |||
*Has been evaluated as a first-line screening test for predicting the risk of GG2+ prostate cancers.[https://pubmed.ncbi.nlm.nih.gov/26563502/] | |||
**STHLM-3 found to have a higher predictive accuracy compared to PSA alone (area under the curve [AUC] 0.74 versus 0.56) and reduced unnecessary biopsies by 32% | |||
** Further validation in diverse populations to confirm these findings will be necessary to move forward into practice. | |||
==== Polygenic risk score (PRS) ==== | |||
* Genetic tests used to predict a person’s risk of developing prostate cancer. | |||
*Typically constructed as the weighted sum of a collection of genetic variants, usually single nucleotide polymorphisms (SNPs) defined as single base-pair variations from the reference genome[https://pubmed.ncbi.nlm.nih.gov/35251129/] | |||
*Little evidence to mandate which SNP panel or PRS to use and where to threshold risk to create strata with different screening intensities. | |||
*At the time of evidence review, no PRS tool has been shown to discriminate between aggressive and indolent prostate cancer risk | |||
== Questions == | == Questions == | ||
# What is the optimal MRI sequence to evaluate | #What is the function of PSA? What is the half life? | ||
#How does PSA circulate in the blood? | |||
#When does serum PSA become detectable? | |||
#What is the optimal MRI sequence to evaluate | |||
## Hemorrhage | ## Hemorrhage | ||
## Transition zone | ## Transition zone | ||
| Line 475: | Line 831: | ||
## Peripheral zone | ## Peripheral zone | ||
# Describe the PROMIS and PRECISION trials | # Describe the PROMIS and PRECISION trials | ||
#What is the differential diagnosis for an area of low signal intensity on T2WI? | |||
== Answers == | == Answers == | ||
== Next Chapter: [ | #What is the function of PSA? What is the half life?#*Liquify semen | ||
#* 2-3 days | |||
#How does PSA circulate in the blood? | |||
#*Circulates free (20-30%) and bound (70-80%). | |||
#*Bound to 3 proteins: α1-antichymotripson, α2-macroglobulin, α1-protease inhibitor | |||
#When does serum PSA become detectable? | |||
#*Puberty | |||
#What is the optimal MRI sequence to evaluate | |||
## Hemorrhage | |||
## Transition zone | |||
## Vascularity of the prostate | |||
## Peripheral zone | |||
# Describe the PROMIS and PRECISION trials | |||
#What is the differential diagnosis for an area of low signal intensity on T2WI? | |||
== Next Chapter: [https://test.urologyschool.com/index.php/Prostate%20Cancer:%20Blood,%20Urine%20and%20Tissue-based%20markers Blood, Urine and Tissue-based Markers] == | |||
== References == | == References == | ||
* Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, chap 111 | * Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, chap 108 | ||
* AUA Update Series (2016) Lesson 14: Multiparametric Magnetic Resonance Imaging for Prostate Cancer | *Wein AJ, Kavoussi LR, Partin AW, Peters CA (eds): CAMPBELL-WALSH UROLOGY, ed 11. Philadelphia, Elsevier, 2015, chap 111 | ||
* [https://pubmed.ncbi.nlm.nih.gov/12525533/ Balk, Steven P., Yoo-Joung Ko, and Glenn J. Bubley.] "Biology of prostate-specific antigen." ''Journal of clinical oncology'' 21.2 (2003): 383-391. | |||
*AUA Update Series (2016) Lesson 14: Multiparametric Magnetic Resonance Imaging for Prostate Cancer | |||
* [https://pubmed.ncbi.nlm.nih.gov/33661093/ Shaygan, Bobby, et al.] "Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer." ''Canadian Urological Association Journal'' 15.6 (2021): 162. | * [https://pubmed.ncbi.nlm.nih.gov/33661093/ Shaygan, Bobby, et al.] "Canadian Urological Association best practice report: Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate cancer." ''Canadian Urological Association Journal'' 15.6 (2021): 162. | ||